NKTX (Nkarta) Dividends per Share : $0.00 (TTM As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Nkarta Dividends per Share?

Nkarta's dividends per share for the three months ended in Dec. 2024 was $0.00. Its dividends per share for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00. Its Dividend Payout Ratio for the three months ended in Dec. 2024 was 0.00. As of today, Nkarta's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.

Nkarta Dividends per Share Historical Data

The historical data trend for Nkarta's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nkarta Dividends per Share Chart

Nkarta Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dividends per Share

Get a 7-Day Free Trial

Nkarta Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Dividends per Share	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Nkarta's Dividends per Share

For the Biotechnology subindustry, Nkarta's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nkarta's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nkarta's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Nkarta's Dividend Yield % falls into.

Save Embed

;

Save Embed

;

Nkarta Dividends per Share Calculation

Dividends paid to per common share.

Nkarta (NAS:NKTX) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Nkarta's Dividend Payout Ratio for the quarter that ended in Dec. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2024 )	/	EPS without NRI (Q: Dec. 2024 )
	=	0	/	-0.35
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

Nkarta Dividends per Share Related Terms

Thank you for viewing the detailed overview of Nkarta's Dividends per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Nkarta Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nkarta Inc (NAS:NKTX) » Definitions » Dividends per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

1150 Veterans Boulevard, South San Francisco, CA, USA, 94080

Website

https://www.nkartatx.com

Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.

Executives

Alyssa Levin	officer: See Remarks	6000 SHORELINE COURT, SUITE 102, SOUTH SAN FRANCISCO CA 94080
Paul J Hastings	director, officer: See Remarks	61 HARTFORD STREET, SAN FRANCISCO CA 94114
Ralph Brandenberger	officer: Sr. VP, Technical Operations	6000 SHORELINE COURT, SUITE 102, SAN FRANCISCO CA 94080
David Shook	officer: Chief Medical Officer	6000 SHORELINE COURT, SUITE 102, SOUTH SAN FRANCISCO CA 94080
Alicia J. Hager	officer: Chief Legal Officer	C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
James Trager	officer: Chief Scientific Officer	6000 SHORELINE COURT, SUITE 102, SOUTH SAN FRANCISCO CA 94080
Ra Capital Healthcare Fund Lp	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Simeon George	director	161 WASHINGTON STREET, SUITE 500, CONSHOHOCKEN PA 19428
Nadir Mahmood	officer: Chief Business Officer	6000 SHORELINE COURT, SUITE 102, SOUTH SAN FRANCISCO CA 94080
Angela Thedinga	director	C/O ADVERUM BIOTECHNOLOGIES, INC., 1035 O'BRIEN DRIVE, MENLO PARK CA 94025
Ra Capital Nexus Fund, L.p.	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Kanya Rajangam	officer: Chief Medical Officer	C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080
James E Flynn	10 percent owner, other: Possible Member of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Ra Capital Management, L.p.	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900